Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells

Current Medicinal Chemistry

Volumn 21, Issue 14, 2014, Pages 1607-1617

  Maina, Flavio ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Cell plasticity; Mechanism of drug action; Oncogenic RTKs; Resistance mechanisms; RTK anticancer agents; RTK addiction

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 CHLORO 3 [(3,5 DIMETHYL 2 PYRROLYL)METHYLENE] 2 INDOLINONE; AMG 888; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; ERTUMAXOMAB; GEFITINIB; IMATINIB; IMIDAZO[2,1 B]BENZOTHIAZOL-2-YLPHENYL DERIVATIVE; IMIDAZO[2,1 B]BENZOTHIAZOLE DERIVATIVE; LAPATINIB; LESTAURTINIB; MIDOSTAURIN; MONOCLONAL ANTIBODY 391; NINTEDANIB; NVP AEW 541; PERTUZUMAB; PICTILISIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; RANIBIZUMAB; SEMAXANIB; SORAFENIB; TIVANTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTEIN KINASE INHIBITOR;

CANCER CELL; CANCER RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE MUTATION; GENOME; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NEOPLASMS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84899822483     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990222     Document Type: Review

References (103)

1. Nowell, P.C. The clonal evolution of tumor cell populations. Science, 1976, 194, 23-28.
2. Bissell, M.J.; Hines, W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med., 2011, 17, 320-329.
3. Gerlinger, M.; Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer, 2010, 103, 1139-1143.
4. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov., 2004, 3, 1001-1010.
5. Greenman, C.; Stephens, P.; Smith, R.; Dalgliesh, G.L.; Hunter, C.; Bignell, G.; Davies, H.; Teague, J.; Butler, A.; Stevens, C.; Edkins, S.; O'Meara, S.; Vastrik, I.; Schmidt, E.E.; Avis, T.; Barthorpe, S.; Bhamra, G.; Buck, G.; Choudhury, B.; Clements, J.; Cole, J.; Dicks, E.; Forbes, S.; Gray, K.; Halliday, K.; Harrison, R.; Hills, K.; Hinton, J.; Jenkinson, A.; Jones, D.; Menzies, A.; Mironenko, T.; Perry, J.; Raine, K.; Richardson, D.; Shepherd, R.; Small, A.; Tofts, C.; Varian, J.; Webb, T.; West, S.; Widaa, S.; Yates, A.; Cahill, D.P.; Louis, D.N.; Goldstraw, P.; Nicholson, A.G.; Brasseur, F.; Looijenga, L.; Weber, B.L.; Chiew, Y.E.; DeFazio, A.; Greaves, M.F.; Green, A.R.; Campbell, P.; Birney, E.; Easton, D.F.; Chenevix-Trench, G.; Tan, M.H.; Khoo, S.K.; The, B.T.; Yuen, S.T.; Leung, S.Y.; Wooster, R.; Futreal, P.A.; Stratton, M.R. Patterns of somatic mutation in human cancer genomes. Nature, 2007, 446, 153-158.
6. Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141, 1117-1134.
7. Carpenter, G.; Pozzi, A. Cell responses to growth factors: the role of receptor tyrosine kinase intracellular domain fragments. Sci. Signal., 2012, 5, pe42.
8. Kolch, W.; Pitt, A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer, 2010, 10, 618-629.
9. Weinstein, I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science, 2002, 297, 63-64.
10. Sharma, S.V.; Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev., 2007, 21, 3214-3231.
11. Zwick, E.; Bange, J.; Ullrich, A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med., 2002, 8, 17-23.
12. Carlomagno, F.; Santoro, M. Receptor tyrosine kinases as targets for anticancer therapeutics. Curr. Med. Chem., 2005, 12, 1773-1781.
13. Petrelli, A.; Giordano, S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem., 2008, 15, 422-432.
14. Wahl, O.; Oswald, M.; Tretzel, L.; Herres, E.; Arend, J.; Efferth, T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr. Med. Chem., 2011, 18, 3136-3155.
15. Chaudhary, N.I.; Roth, G.J.; Hilberg, F.; Muller-Quernheim, J.; Prasse, A.; Zissel, G.; Schnapp, A.; Park, J.E. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J., 2007, 29, 976-985.
16. Knapper, S.; Burnett, A.K.; Littlewood, T.; Kell, W.J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M.J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108, 3262-3270.
17. Weisberg, E.; Boulton, C.; Kelly, L.M.; Manley, P.; Fabbro, D.; Meyer, T.; Gilliland, D.G.; Griffin, J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell., 2002, 1, 433-443.
18. Weisberg, E.; Manley, P.W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S.W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A.L.; Mestan, J.; Daley, G.Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R.D.; Gilliland, D.G.; Griffin, J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell., 2005, 7, 129-141.
19. Yee, K.W.; O'Farrell, A.M.; Smolich, B.D.; Cherrington, J.M.; McMahon, G.; Wait, C.L. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 2002, 100, 2941-2949.
20. O'Farrell, A.M.; Abrams, T.J.; Yuen, H.A.; Ngai, T.J.; Louie, S.G.; Yee, W. H.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003, 101, 3597-3605.
21. Kelly, L.M.; Yu, J.C.; Boulton, C.L.; Apatira, M.; Li, J.; Sullivan, C.M.; Williams, I.; Amaral, S.M.; Curley, D.P.; Duclos, N.; Neuberg, D.; Scarborough, R.M.; Pandey, A.; Hollenbach, S.; Abe, K.; Lokker, N.A.; Gilliland, D.G.; Giese, N.A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell., 2002, 1, 421-432.
22. Garuti, L.; Roberti, M.; Bottegoni, G. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem., 2010, 17, 2804-2821.
23. Bogoyevitch, M.A.; Fairlie, D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today, 2007, 12, 622-633.
24. Munshi, N.; Jeay, S.; Li, Y.; Chen, C.R.; France, D.S.; Ashwell, M.A.; Hill, J.; Moussa, M.M.; Leggett, D.S.; Li, C.J. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther., 2010, 9, 1544-1553.
25. Buttner, A.; Cottin, T.; Xu, J.; Tzagkaroulaki, L.; Giannis, A. Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors. Bioorg. Med. Chem., 2010, 18, 3387-3402.
26. Steiner, L.; Blum, G.; Friedmann, Y.; Levitzki, A. ATP noncompetitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur. J. Pharmacol., 2007, 562, 1-11.
27. Wissner, A.; Floyd, M.B.; Johnson, B.D.; Fraser, H.; Ingalls, C.; Nittoli, T.; Dushin, R.G.; Discafani, C.; Nilakantan, R.; Marini, J.; Ravi, M.; Cheung, K.; Tan, X.; Musto, S.; Annable, T.; Siegel, M.M.; Loganzo, F. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. J. Med. Chem., 2005, 48, 7560-7581.
28. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer, 2006, 6, 714-727.
29. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Vande Woude, G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer, 2012, 12, 89-103.
30. Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov., 2004, 3, 391-400.
31. Baselga, J.; Swain, S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer, 2009, 9, 463-475.
32. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer, 2012, 12, 159-169.
33. Carter, P.; Presta, L.; Gorman, C.M.; Ridgway, J.B.; Henner, D.; Wong, W.L.; Rowland, A.M.; Kotts, C.; Carver, M.E.; Shepard, H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U S A, 1992, 89, 4285-4289.
34. Jin, H.; Yang, R.; Zheng, Z.; Romero, M.; Ross, J.; Bou-Reslan, H.; Carano, R.A.; Kasman, I.; Mai, E.; Young, J.; Zha, J.; Zhang, Z.; Ross, S.; Schwall, R.; Colbern, G.; Merchant, M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res., 2008, 68, 4360-4368.
35. Dancey, J.E.; Chen, H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 2006, 5, 649-659.
36. Pallis, A.; Briasoulis, E.; Linardou, H.; Papadimitriou, C.; Bafaloukos, D.; Kosmidis, P.; Murray, S. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr. Med. Chem., 2011, 18, 1613-1628.
37. Cruz-Lopez, O.; Conejo-Garcia, A.; Nunez, M.C.; Kimatrai, M.; Garcia-Rubino, M.E.; Morales, F.; Gómez-Pérez, V.; Campos, J.M. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. Curr. Med. Chem., 2011, 18, 943-963.
38. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer, 2007, 7, 169-181.
39. Pao, W.; Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer, 2010, 10, 760-774.
40. Monteleone, F.; Rosa, R.; Vitale, M.; D'Ambrosio, C.; Succoio, M.; Formisano, L.; Nappi, L.; Romano, M.F.; Scaloni, A.; Tortora, G.; Bianco, R.; Zambrano, N. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics, 2013, 13(5), 866-877.
41. Crespan, E.; Zucca, E.; Maga, G. Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models. Curr. Med. Chem., 2011, 18, 2836-2847.
42. Sawyers, C.L. Cancer: mixing cocktails. Nature, 2007, 449, 993-996.
43. Knudsen, B.S.; Vande Woude, G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev., 2008, 18, 87-96.
44. Trusolino, L.; Bertotti, A.; Comoglio, P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell. Biol., 2010, 11, 834-848.
45. Cui, J.J. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Exp. Opin. Ther. Patents, 2007, 17, 1035-1045.
46. Underiner, T.L.; Herbertz, T.; Miknyoczki, S.J. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med. Chem., 2010, 10, 7-27.
47. Stommel, J.M.; Kimmelman, A.C.; Ying, H.; Nabioullin, R.; Ponugoti, A.H.; Wiedemeyer, R.; Stegh, A.H.; Bradner, J.E.; Ligon, K.L.; Brennan, C.; Chin, L.; DePinho, R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318, 287-290.
48. Druker, B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res., 2004, 91, 1-30.
49. Snuderl, M.; Fazlollahi, L.; Le, L.P.; Nitta, M.; Zhelyazkova, B.H.; Davidson, C.J.; Akhavanfard, S.; Cahill, D.P.; Aldape, K.D.; Betensky, R.A.; Louis, D.N.; Iafrate, A.J. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell., 2011, 20, 810-817.
50. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Jänne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316, 1039-1043.
51. Turke, A.B.; Zejnullahu, K.; Wu, Y.L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; Toschi, L.; Rogers, A.; Mok, T.; Sequist, L.; Lindeman, N.I.; Murphy, C.; Akhavanfard, S.; Yeap, B.Y.; Xiao, Y.; Capelletti, M.; Iafrate, A.J.; Lee, C.; Christensen, J.G.; Engelman, J.A.; Jänne, P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell., 2010, 17, 77-88.
52. Shattuck, D.L.; Miller, J.K.; Carraway, K.L.; 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res., 2008, 68, 1471-1477.
53. McDermott, U.; Pusapati, R.V.; Christensen, J.G.; Gray, N.S.; Settleman, J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res., 2010, 70, 1625-1634.
54. Bachleitner-Hofmann, T.; Sun, M.Y.; Chen, C.T.; Tang, L.; Song, L.; Zeng, Z.; Shah, M.; Christensen, J.G.; Rosen, N.; Solit, D.B.; Weiser, M.R. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol. Cancer Ther., 2008, 7, 3499-3508.
55. Dewaele, B.; Floris, G.; Finalet-Ferreiro, J.; Fletcher, C.D.; Coindre, J.M.; Guillou, L.; Hogendoorn, P.C.; Wozniak, A.; Vanspauwen, V.; Schöffski, P.; Marynen, P.; Vandenberghe, P.; Sciot, R.; Debiec-Rychter, M. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res., 2010, 70, 7304-7314.
56. Liska, D.; Chen, C.T.; Bachleitner-Hofmann, T.; Christensen, J.G.; Weiser, M.R. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin. Cancer Res., 2011, 17, 472-482.
57. Guo, A.; Villen, J.; Kornhauser, J.; Lee, K.A.; Stokes, M.P.; Rikova, K.; Possemato, A.; Nardone, J.; Innocenti, G.; Wetzel, R.; Wang, Y.; MacNeill, J.; Mitchell, J.; Gygi, S.P.; Rush, J.; Polakiewicz, R.D.; Comb, M.J. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U S A, 2008, 105, 692-697.
58. Bache, K.G.; Slagsvold, T.; Stenmark, H. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J., 2004, 23, 2707-2712.
59. Lill, N.L.; Sever, N.I. Where EGF receptors transmit their signals. Sci. Signal., 2012, 5, pe41.
60. Choudhary, C.; Olsen, J.V.; Brandts, C.; Cox, J.; Reddy, P.N.; Bohmer, F.D.; Gerke, V.; Schmidt-Arras, D.E.; Berdel, W.E.; Müller-Tidow, C.; Mann, M.; Serve, H. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell., 2009, 36, 326-339.
61. Joffre, C.; Barrow, R.; Menard, L.; Calleja, V.; Hart, I.R.; Kermorgant, S. A direct role for Met endocytosis in tumorigenesis. Nat. Cell. Biol., 2011, 13, 827-837.
62. Clague, M.J. Met receptor: a moving target. Sci. Signal., 2011, 4, pe40.
63. Goldschneider, D.; Mehlen, P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene, 2010, 29, 1865-1882.
64. Mehlen, P.; Bredesen, D.E. Dependence receptors: from basic research to drug development. Sci. Signal., 2011, 4, mr2.
65. Tulasne, D.; Deheuninck, J.; Lourenco, F.C.; Lamballe, F.; Ji, Z.; Leroy, C.; Puchois, E.; Moumen, A.; Maina, F.; Mehlen, P.; Fafeur, V. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol. Cell. Biol., 2004, 24, 10328-10339.
66. Foveau, B.; Leroy, C.; Ancot, F.; Deheuninck, J.; Ji, Z.; Fafeur, V.; Tulasne, D. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell. Death Differ., 2007, 14, 752-764.
67. Tauszig-Delamasure, S.; Yu, L.Y.; Cabrera, J.R.; Bouzas-Rodriguez, J.; Mermet-Bouvier, C.; Guix, C.; Bordeaux, M.C.; Arumäe, U.; Mehlen, P. The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proc. Natl. Acad. Sci. U S A, 2007, 104, 13361-13366.
68. Lefebvre, J.; Ancot, F.; Leroy, C.; Muharram, G.; Lemiere, A.; Tulasne, D. Met degradation: more than one stone to shoot a receptor down. FASEB. J., 2012, 26, 1387-1399.
69. Genevois, A.L.; Ichim, G.; Coissieux, M.M.; Lambert, M.P.; Lavial, F.; Goldschneider, D.; Jarrosson-Wuilleme, L.; Lepinasse, F.; Gouysse, G.; Herceg, Z.; Scoazec, J.Y.; Tauszig-Delamasure, S.; Mehlen, P. Dependence receptor TrkC is a putative colon cancer tumor suppressor. Proc. Natl. Acad. Sci. U S A, 2013, 110(8), 3017-3022.
70. Bouzas-Rodriguez, J.; Cabrera, J.R.; Delloye-Bourgeois, C.; Ichim, G.; Delcros, J.G.; Raquin, M.A.; Rousseau, R.; Combaret, V.; Bénard, J.; Tauszig-Delamasure, S.; Mehlen, P. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J. Clin. Invest., 2010, 120, 850-858.
71. Cragg, M.S.; Harris, C.; Strasser, A.; Scott, C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer, 2009, 9, 321-326.
72. Bodur, C.; Basaga, H. Bcl-2 inhibitors: emerging drugs in cancer therapy. Curr. Med. Chem., 2012, 19, 1804-1820.
73. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.; Li, Y.; Chen, Y.Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov., 2009, 8, 111-128.
74. Sharma, S.V.; Gajowniczek, P.; Way, I.P.; Lee, D.Y.; Jiang, J.; Yuza, Y.; Classon, M.; Haber, D.A.; Settleman, J. A common signaling cascade may underlie addiction to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell., 2006, 10, 425-435.
75. Bertotti, A.; Burbridge, M.F.; Gastaldi, S.; Galimi, F.; Torti, D.; Medico, E.; Giordano, S.; Corso, S.; Rolland-Valognes, G.; Lockhart, B.P.; Hickman, J.A.; Comoglio, P.M.; Trusolino, L. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal., 2009, 2, er11.
76. Junttila, T.T.; Akita, R.W.; Parsons, K.; Fields, C.; Lewis Phillips, G.D.; Friedman, L.S.; Sampath, D.; Sliwkowski, M.X. Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell., 2009, 15, 429-440.
77. Yadav, V.; Zhang, X.; Liu, J.; Estrem, S.; Li, S.; Gong, X.Q.; Buchanan, S.; Henry, J.R.; Starling, J.J.; Peng, S.B. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human BRAF V600E mutant melanoma. J. Biol. Chem., 2012, 287, 28087-28098.
78. Maina, F.; Casagranda, F.; Audero, E.; Simeone, A.; Comoglio, P.; Klein, R.; Ponzetto, C. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell, 1996, 87, 531-542.
79. Maina, F.; Pante, G.; Helmbacher, F.; Andres, R.; Porthin, A.; Davies, A.M.; Ponzetto, C.; Klein, R. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell., 2001, 7, 1293-1306.
80. Segarra, J.; Balenci, L.; Drenth, T.; Maina, F.; Lamballe, F. Combined Signaling through ERK, PI3K/AKT, and RAC1/p38 Is Required for Met-triggered Cortical Neuron Migration. J. Biol. Chem., 2006, 281, 4771-4778.
81. Moumen, A.; Ieraci, A.; Patane, S.; Sole, C.; Comella, J.X.; Dono, R.; Maina F. Met signals hepatocyte survival by preventing Fastriggered FLIP degradation in a PI3k-Akt-dependent manner. Hepatology, 2007, 45, 1210-1217.
82. Moumen, A.; Patane, S.; Porras, A.; Dono, R.; Maina, F. Met acts on Mdm2 via mTOR to signal cell survival during development. Development, 2007, 134, 1443-1451.
83. Lamballe, F.; Genestine, M.; Caruso, N.; Arce, V.; Richelme, S.; Helmbacher, F.; Maina, F. Pool-specific regulation of motor neuron survival by neurotrophic support. J. Neurosci., 2011, 31, 11144-11158.
84. Blume-Jensen, P.; Liang, G.; Hyman, R.; Lee, K.F.; O'Gorman, S.; Hunter, T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. Nat Genet., 2000, 24, 157-162.
85. Kissel, H.; Timokhina, I.; Hardy, M.P.; Rothschild, G.; Tajima, Y.; Soares, V.; Angeles, M.; Whitlow, S.R.; Manova, K.; Besmer, P. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO. J., 2000, 19, 1312-1326.
86. Tallquist, M.D.; Klinghoffer, R.A.; Heuchel, R.; Mueting-Nelsen, P.F.; Corrin, P.D.; Heldin, C.H.; Johnson, R.J.; Soriano, P. Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase Cgamma signaling pathways. Genes. Dev., 2000, 14, 3179-3190.
87. Klinghoffer, R.A.; Mueting-Nelsen, P.F.; Faerman, A.; Shani, M.; Soriano, P. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol. Cell., 2001, 7, 343-354.
88. Asai, N.; Fukuda, T.; Wu, Z.; Enomoto, A.; Pachnis, V.; Takahashi, M.; Costantini, F. Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. Development, 2006, 133, 4507-4516.
89. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 2006, 5, 835-844.
90. Ranieri, G.; Gadaleta-Caldarola, G.; Goffredo, V.; Patruno, R.; Mangia, A.; Rizzo, A.; Sciorsci, R.L.; Gadaleta, C.D. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr. Med. Chem., 2012, 19, 938-944.
91. Apsel, B.; Blair, J.A.; Gonzalez, B.; Nazif, T.M.; Feldman, M.E.; Aizenstein, B.; Hoffman, R.; Williams, R.L.; Shokat, K.M.; Knight, Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol., 2008, 4, 691-699.
92. Asses, Y.; Leroux, V.; Tairi-Kellou, S.; Dono, R.; Maina, F.; Maigret, B. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands. Chem. Biol. Drug Des., 2009, 74, 560-570.
93. Patane, S.; Pietrancosta, N.; Hassani, H.; Leroux, V.; Maigret, B.; Kraus, J.L.; Dono, R.; Maina, F. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen. Biochem. Biophys. Res. Commun., 2008, 375, 184-189.
94. Furlan, A.; Colombo, F.; Kover, A.; Issaly, N.; Tintori, C.; Angeli, L.; Leroux, V.; Letard, S.; Amat, M.; Asses, Y.; Maigret, B.; Dubreuil, P.; Botta, M.; Dono, R.; Bosch, J.; Piccolo, O.; Passarella, D.; Maina, F. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. Eur. J. Med. Chem., 2012, 47, 239-254.
95. Furlan, A.; Roux, B.; Lamballe, F.; Conti, F.; Issaly, N.; Daian, F.; Guillemot, J.F.; Richelme, S.; Contensin, M.; Bosch, J.; Passarella, D.; Piccolo, O.; Dono, R.; Maina, F. Combined drug action of 2-phenylimidazo[2,1-b] benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures. PLoS One, 2012, 7, e46738.
96. Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.
97. Bild, A.H.; Yao, G.; Chang, J.T.; Wang, Q.; Potti, A.; Chasse, D.; Joshi, M.B.; Harpole, D.; Lancaster, J.M.; Berchuck, A.; Olson, J.A. Jr., Marks, J.R.; Dressman, H.K.; West, M.; Nevins, J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 2006, 439, 353-357.
98. Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjoblom, T.; Leary, R.J.; Shen, D.; Boca, S.M.; Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.; Karchin, R.; Wilson, P.A.; Kaminker, J.S.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; Willson, J.K.; Sukumar, S.; Polyak, K.; Park, B.H.; Pethiyagoda, C.L.; Pant, P.V.; Ballinger, D.G.; Sparks, A.B.; Hartigan, J.; Smith, D.R.; Suh, E.; Papadopoulos, N.; Buckhaults, P.; Markowitz, S.D.; Parmigiani, G.; Kinzler, K.W.; Velculescu, V.E.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science, 2007, 318, 1108-1113.
99. Li, D.; Gad, G.; David, A. W.; Elaine, R. M.; Michael, D. M.; Kristianm C, Carrie, S.; Heidi, G.; Donna, M. M.; Margaret, B. M.; Lucinda, F.; Robert, S. F.; Qunyuan, Z.; Michael, C. W.; Michael, S. L.; David, E. L.; Ken, C.; David, J. D.; Aniko, S.; Alicia, C. H.; Hua, S.; Shalini, N. J.; Lora, R. L.; Otis, H.; Yiming, Z.; Tittu, M.; Yanru, R.; Jiqiang, Y.; Steven, E. S.; Kerstin, C.; Ginger, A. M.; Brian, N.; Aleksandar, M.; Manuel, L. G.-G.; John, R. O.; Rick, M.; Xiaoqi, S.; Yuzhu, T.; Daniel, C. K.; Ling, L.; Rachel, A.; Tracie, L. M.; Craig, P.; Ginger, F.; Carrie, H.; Heather, S.; Brian, H. D.-S.; Aldi, K.; Seth, D. C.; Christopher, S. S.; Tammi, V.; Sacha, S.; Jody, R.; Wendy, W.; Jennifer, B.; Lucian, R. C.; Amit, D.; Tim, F.; Megan, H.; Bruce, E. J.; Robert, C. O.; Roman, K. T.; Giovanni, T.; Barbara, A. W.; Xiaojun, Z.; Liuda, Z.; Michael, C. Z.; Thomas, G.; Mark, B. O.; Jack, A. R.; Margaret, R. S.; Ignacio, I. W.; Bradley, O.; Peter, J. G.; Andrew, C. C.; David, G. B.; Mark, A. W.; Marc, L.; Stephen, B.; Akihiko, Y.; William, D. T.; William, P.; Michael, A. P.; George, M. W.; Harold, E. V.; Stacey, B. G.; Eric, S. L.; Richard, A. G.; Matthew, M.; Richard, K. W. Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.
100. Furlan, A.; Lamballe, F.; Stagni, V.; Hussain, A.; Richelme, S.; Prodosmo, A.; Moumen, A.; Brun, C..; Del Barco Barrantes, I.; Arthur, J.S.; Koleske, A.J.; Nebreda, A.R.; Barila, D.; Maina, F. Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. J. Hepatol., 2012, 57, 1292-1298.
101. Furlan, A.; Stagni, V.; Hussain, A.; Richelme, S.; Conti, F.; Prodosmo, A.; Destro A.; Roncalli, M.; Barila, D.; Maina, F. Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ., 2011, 18, 1608-1616.
102. Sturm, O.E.; Orton, R.; Grindlay, J.; Birtwistle, M.; Vyshemirsky, V.; Gilbert, D.; Calder, M.; Pitt, A.; Kholodenko, B.; Kolch, W. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci. Signal., 2010, 3, ra90.
103. Stains, C.I.; Tedford, N.C.; Walkup, T.C.; Lukovic, E.; Goguen, B.N.; Griffith, L.G.; Lauffenburger, D.A.; Imperiali, B. Interrogating signaling nodes involved in cellular transformations using kinase activity probes. Chem. Biol., 2012, 19, 210-217.